We hope that the results of prospective randomized trials, such as the PERSEE trial evaluating pembrolizumab versus pembrolizumab in combination with CT in advanced-stage NSCLC with PD-L1 TPS ≥50%, will provide some answers [72]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.